FDA regulatory considerations for oncology drug development
Pharmacology Research & Perspectives · 2024
DOI: 10.1002/prp2.1254 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2024. Verfasst von Hanlim Moon und 6 weiteren Autor:innen. Beteiligte Einrichtung: MediRama, Inc., Seoul, South Korea. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Drug Development, Antineoplastic Agents, Drug Approval. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- MediRama, Inc., Seoul, South Korea.
- Department of Internal Medicine, College of Medicine, Hallym University, Hallym University Sacred Heart Hospital, Anyang-si, South Korea.
- Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
- Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia.
ORCID-Profile: Hanlim Moon, Dae Young Zang, Min-Hee Ryu, YeonSook Seo, Bitna Oh, Lee Farrand
Zitieren
APA
Moon, H., Zang, D. Y., Ryu, M. H., Seo, Y., Oh, B., Hwang, S., & Farrand, L. (2024). FDA regulatory considerations for oncology drug development. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.1254
Vancouver
Moon H, Zang DY, Ryu MH, Seo Y, Oh B, Hwang S, et al. FDA regulatory considerations for oncology drug development. Pharmacology Research & Perspectives. 2024. doi:10.1002/prp2.1254
BibTeX
@article{Moon2024,
author = {Moon, Hanlim and Zang, Dae Young and Ryu, Min-Hee and Seo, YeonSook and Oh, Bitna and Hwang, Sunjin and Farrand, Lee},
title = {FDA regulatory considerations for oncology drug development},
journal = {Pharmacology Research & Perspectives},
year = {2024},
doi = {10.1002/prp2.1254}
}
EUVIMED